# Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease

> **NCT05506488** · PHASE1,PHASE2 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 30 (actual)

## Conditions studied

- NAFLD
- NASH With Fibrosis
- Liver Fibrosis

## Interventions

- **DRUG:** Dasatinib 100 MG + Quercetin (1000 MG)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05506488
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-05
- **Primary completion:** 2026-02-26
- **Final completion:** 2026-02-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506488, "Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05506488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*